UniQure appoints 2 board members
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
Amsterdam-based gene therapy company uniQure NV appointed Robert Gut and David Meek to the board.
Gut is currently the chief medical officer for Versartis Inc. Meek has been the CEO of Ipsen SA since 2016.